Alkermes has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck, for a planned phase 3 study to evaluate nemvaleukin alfa, Alkermes’ novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD’s Keytruda (pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer.   Alkermes is responsible for conducting the phase 3 study, which is planned to...